Revenue increased 8.4%
Revenue changed +8.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Revenue changed +8.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Current liabilities changed +20.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Noncurrent long-term debt changed +55.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Stock-based compensation changed +362.5% from the comparable as-filed period.
Debt / revenue changed +1402 basis points from the comparable as-filed period.
Receivables / revenue changed -1446 basis points from the comparable as-filed period.
Net income changed +14.5% from the comparable as-filed period.
SBC / revenue changed +242 basis points from the comparable as-filed period.
Working capital / assets changed -576 basis points from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Operating cash-flow margin changed -1198 basis points from the comparable as-filed period.
Trade receivables changed -14.1% from the comparable as-filed period.
Current assets changed +12.1% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Research & development changed +3.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Total assets changed +0.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Current ratio changed -6.7% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Cash / debt changed +29 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
R&D / revenue changed -29 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.